

2005

Genetic epidemiology of diabetes

M. Alan Permutt

Washington University School of Medicine in St. Louis

Jonathon Wasson

Washington University School of Medicine in St. Louis

Nancy Cox

University of Chicago

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Permutt, M. Alan; Wasson, Jonathon; and Cox, Nancy, "Genetic epidemiology of diabetes." *The Journal of Clinical Investigation*. 115, 6. 1431-1439. (2005).

https://digitalcommons.wustl.edu/open_access_pubs/1460

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.



Genetic epidemiology of diabetes

M. Alan Permutt,¹ Jonathon Wasson,¹ and Nancy Cox²

¹Department of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA.

²Department of Human Genetics, The University of Chicago, Chicago, Illinois, USA.

Conventional genetic analysis focuses on the genes that account for specific phenotypes, while traditional epidemiology is more concerned with the environmental causes and risk factors related to traits. Genetic epidemiology is an alliance of the 2 fields that focuses on both genetics, including allelic variants in different populations, and environment, in order to explain exactly how genes convey effects in different environmental contexts and to arrive at a more complete comprehension of the etiology of complex traits. In this review, we discuss the epidemiology of diabetes and the current understanding of the genetic bases of obesity and diabetes and provide suggestions for accelerated accumulation of clinically useful genetic information.

Definition of the problem

Diabetes is a metabolic condition in which the body fails to produce enough insulin. Type 1 diabetes (T1D) results from autoimmune destruction of insulin-producing β cells, which leaves the patient dependent on insulin injections for survival (1). T2D, formerly known as adult-onset diabetes, occurs when impaired insulin effectiveness (insulin resistance) is accompanied by the failure to produce sufficient β cell insulin. Patients can be placed on regimens to reduce weight or manage diet or treated with medication and, less often, insulin injections. This latter form of diabetes accounts for as much as 95% of cases. Gestational diabetes is another form of diabetes, defined as a state of glucose intolerance during pregnancy that usually subsides after delivery but has major implications for subsequent risk of T2D, as pregnancy serves as an “environmental” stressor that reveals a genetic predisposition. Other less common forms of diabetes include the rare, genetically determined disease maturity onset diabetes of the young (MODY), diabetes resulting from surgery, and other illnesses that constitute only 1–5% of cases. Based on plasma glucose measurements, 2 conditions have been identified with increased risk of the disease (2): (a) impaired glucose tolerance (IGT) is defined as hyperglycemia intermediate between normal and diabetic levels following a glucose load; (b) impaired fasting glucose (IFG), like IGT, is associated with increased cardiovascular disease (CVD) and future diabetes. Because complications of diabetes may develop years before overt disease, many consider the disease part of a cluster of CVD risk factors that include hypertension, hyperinsulinemia, dyslipidemia, visceral obesity, hypercoagulability, and microalbuminuria. This collection of risk factors is also known as the metabolic syndrome (3, 4).

While insulin therapy can reverse many of the metabolic disturbances, and numerous improvements in management have been introduced (5), the disease has reached epidemic proportions. According to the WHO (6), it is likely to be one of the most substantial threats to human health in the 21st century.

Nonstandard abbreviations used: ASP, affected sibling pair; CVD, cardiovascular disease; DZ, dizygotic; IGT, impaired glucose tolerance; IRAS, Insulin Resistance Atherosclerosis Study; MODY, maturity onset diabetes of the young; MZ, monozygotic; SNP, single nucleotide polymorphism; T1D, type 1 diabetes; T2D, type 2 diabetes; VNTR, variable number of tandem repeats.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 115:1431–1439 (2005). doi:10.1172/JCI24758.

Prevalence


The prevalence of diabetes in the United States has risen 40%, from 4.9% in 1990 to 6.9% in 1999 (7). A breakdown of the prevalence of diabetes by state from 1990 through 2001 and of obesity by state from 1991 through 2003 is shown in Figure 1, A and B, respectively (8, 9). The disease affects various groups differently, occurring 10 times more commonly in those older than 65 years compared with those younger than 45 years. Minority racial groups including Hispanics, African Americans, and Native Americans are generally affected at a rate 2–4 times that for white individuals. The recent increased prevalence has also been noted in children and adolescents, where T2D may now occur more commonly than T1D (10). The estimated lifetime risk of developing diabetes for individuals born in the United States in 2000 is 33% for males and 39% for females (7). It is highest among Hispanic females, at 53%. Diabetes is associated with large reductions in life expectancy, on the order of 11 years in males diagnosed at age 40. While an estimated 18.2 million persons had diabetes in the United States in 2002 (11), diabetes worldwide has been estimated to affect 151 million persons, and that number projected to increase to 324 million by 2025 (2).

The medical burden of diabetes

The burden of diabetes is to a large extent the consequence of macrovascular and microvascular complications of the disease, which result in large increases in morbidity and mortality. For example, the prevalence of ischemic heart disease is 2–14 times the rate in age-matched nondiabetics (12). Diabetic retinopathy is the chief cause of blindness in the US. In 2000, diabetic renal disease accounted for 40% of new cases of end-stage renal disease, and diabetics are the largest group receiving dialysis (more than 50% of all cases) and renal transplants (approximately 25%). Lower extremity disease resulting from a combination of peripheral vascular disease and neuropathy causes an increase in lower extremity amputations. While improved glycemic control has been shown to reduce the incidence of microvascular complications, episodes of severe symptomatic hypoglycemia were 3 times higher in those receiving intensive insulin management therapy (13). Along with experiencing physical and cognitive disabilities, adults with diabetes have an age-adjusted mortality rate estimated to be twice that of nondiabetics (12). Risk factors for CVD, including systolic hypertension, elevated cholesterol levels, and cigarette smoking, independently predict CVD mortality, and any 1 risk factor affects outcomes more in persons with diabetes (14).



review series

**Figure 1**

(A) Diabetes trends among adults in the US. *Includes gestational diabetes. Adapted from ref. 8. (B) Obesity trends among US adults. **BMI \geq 30 (about 30 pounds overweight for a 5-ft 4-in. individual). Adapted from ref. 9.

Although increase in diabetes prevalence occurs mostly in middle-aged and older adults, there is strong evidence of an increase in the prevalence of T2D in children (10). For example, in Japan the incidence in school children (6–15 years old) has doubled over a 20-year period, such that T2D is now more common than T1D (15). In the US, up to 45% of the newly diagnosed diabetics in the pediatric age group have T2D (10). This rise in diabetes rates in children reflects, at least in part, the growing prevalence of obesity in this age group (16).

Direct medical expenditures and lost productivity due to diabetes were estimated to cost the US \$132 billion in 2002 (17). The per capita expenditures were twice those for individuals without the disease. While the prevalence of diagnosed diabetes is less than 5% of the population, almost \$1 of every \$5 spent on health care in the US is for patients with diabetes. As the prevalence of diabetes increases with age, and because of the increasing diabetes-prone populations, it has been estimated that the number of diagnosed cases will increase. Thus the projected total cost in 2002 dollars could be as high as \$192 billion by 2020.

Etiology of the diabetes epidemic

The sudden increase in diabetes in the last few years is due not to genetic factors but rather to the increase in obesity. This phenomenon is currently being documented in Africa, where the incidence of diabetes is rising with urbanization. The incidence is also rising among Africans who have immigrated to the US (18, 19). Epidemiological studies have regularly shown the relationship between diabetes and obesity, mediated in part by nutritional and lifestyle factors (20, 21). The most common measure of obesity, body mass index (BMI), combines measurements of height and weight. People with a BMI greater than 25 are said to be overweight, while those with a BMI greater than 30 are defined as obese (22). The Nurses Health Study showed that the risk for developing diabetes increased sharply for individuals observed as having a BMI greater than 23 for 16 years and was increased 20-fold for those with a BMI greater than 30 (18). In a recent study of measures of obesity and CVD risk factors in Australian adults, the prevalence of T2D rose from 5% in normal-weight to 16% in obese males; of hypertension, from 20% to 49%; and of dyslipidemia, from 18% to 61%, with even higher prevalence in females (23).

The molecular and physiological relationships between obesity and diabetes are not fully understood, and this subject is an area of intense investigation (see ref. 22 for review). The “thrifty genotype” hypothesis was proposed to account for a genetic advantage of accelerated fat deposition during times of restricted availability of calories, which leaves individuals faced with harmful consequences given the abundant food supply and reduced levels of physical activity in developed countries today (24). Noting an association between low birth weight and increased incidence of diabetes in later life, Hales and Barker have hypothesized that intrauterine malnutrition result in reduced birth weight and to subsequent changes leading to disease in adults (25, 26). This phenomenon, also known as the “thrifty phenotype” hypothesis, proposes that fetal malnutrition results in impaired pancreatic β cell development and insulin resistance. Offspring are subsequently more prone to diabetes and the metabolic syndrome when exposed to abundant nutrition later in life. In this regard, the increased prevalence of T2D in offspring of diabetic mothers may be a consequence of environmental factors operating on a genetic background, i.e., an altered intrauterine environment superimposed on a genetic predisposition in the fetus. While epidemiological studies have confirmed these observations, virtually nothing is known of their mechanisms, and this is an active area of investigation (27). If the relationship between obesity and diabetes could be understood, or obesity effectively prevented with treatment, then therapies directed at these mechanisms might curtail the increasing incidence of the disease.

The relationship between obesity and diabetes has been extensively studied in inbred strains of mice (28). Mice from a single inbred strain fed a high-fat diet all became insulin resistant, yet only about half became both obese and diabetic. Interestingly, 10% became diabetic but resisted obesity, and 10% became obese but not diabetic. The mechanisms responsible are unlikely to be purely genetic, and the results are consistent with the hypothesis that epigenetic changes and stochastic factors contribute to the phenotypic diversity. More recently, ER stress was shown to be the etiology of obesity-induced insulin resistance and diabetes in experimental mouse models, and this mechanism promises to be a rewarding area of investigation in the near future (29). If the degree of ER stress varies among mice, then perhaps this could explain the phenotypic differences in mice that are genetically identical.



As it has long been noted that levels of FFAs are increased in obese individuals, their accumulation in skeletal muscle has been proposed to compete with circulating glucose resulting in hyperglycemia, hyperinsulinemia, and ultimately insulin resistance (30). Recently, using magnetic resonance spectroscopy in patients with obesity and/or T2D, Shulman et al. have shown a reduction in the rate of insulin-stimulated glucose metabolism secondary to reduced muscle glycogen synthesis, associated with a blunted increase in intramuscular glucose 6 phosphate relative to concentration in insulin-resistant offspring of diabetic parents compared to control individuals (31, 32). Increased intracellular fatty acid metabolites were found to result in decreased insulin signaling and impaired glucose transport. Other factors contributing to the insulin resistance of obesity include the tendency to store fat in the abdominal region as opposed to the extremities and defects in adipocyte fatty acid metabolism and mitochondrial fatty acid oxidation. While impaired mitochondrial activity in insulin-resistant offspring of patients with T2D has been observed (33), the genetic basis for reduced mitochondrial biogenesis has not been elucidated. Reduced mitochondrial activity results in reduced energy expenditure, obesity, increased intramuscular fatty acid accumulation, and insulin resistance and has therefore been incorporated into the thrifty gene hypothesis (32).

Heritability of diabetes

The recent increased prevalence of obesity and diabetes must be largely attributable to changes in nongenetic risk factors. Yet environmental aspects must certainly accelerate the disease in those with genetic predisposition. There is a clear need to understand the genetic basis for the regulation of food intake, energy expenditure, and variations in energy balance in various individuals. In the long run, it may be more beneficial to develop treatments based on these genetic mechanisms than to rely on the use of will power to modify lifestyle. Moreover, different aspects of environment may be more critical in different subsets of individuals. We know from the natural history of diabetes complications that when patients are first diagnosed, there may already be marked progression of microvascular and macrovascular complications (34). The overwhelming majority of obese individuals have insulin resistance, yet only 5–10% develop pancreatic β cell failure and diabetes. Discovering the genetic risk factors for the disease will likely have many positive consequences.

The familial occurrences of both T1D and T2D have been long noted. A sibling's risk of developing T1D (5–10%) is perhaps 12- to 100-fold greater than the risk in the general population (0.1–0.4%) (35). Concordance in monozygotic (MZ) twins has been consistently shown to be greater than that in dizygotic (DZ) twins (36). For T2D, the concordance among MZ twins has been observed to be 50–92%, higher than the 37% concordance in DZ twins (36). Thus while the relative risk to a sibling, a measure of the genetic contribution, is considerably greater for T1D than for T2D, the concordance and absolute risk are substantially greater for T2D, which perhaps underscores the importance of the environmental contribution to the latter (37).

Quantitative phenotypes related to glucose homeostasis are also known to be heritable (38). In families with an increased genetic susceptibility to T2D, heritability estimates for β cell function and features of the insulin resistance syndrome of 72% and 78%, respectively, were calculated (39). The heritability of other features of the insulin resistance syndrome, including BMI, blood

pressure, and serum lipid and insulin sensitivity levels, was also estimated to be high. Evidence for heritability of these metabolic phenotypes was reported in studies of Pima Indians (40) and nondiabetic Japanese Americans (41); in the Insulin Resistance Atherosclerosis Study (IRAS) among family members of African American and Hispanic heritage (42); and in a study of the familial aggregation of the amount and distribution of subcutaneous fat and responses to exercise training in the HERITAGE Family Study (43). These studies strongly support the role of both genetic and environmental factors in the etiology of diabetes and the insulin resistance syndrome.

The value of monogenic subtypes of diabetes

Recent reviews provide detailed appraisals of both linkage and association studies in diabetes (38, 44). We focus here on the patterns that have emerged in the search for genetic risk factors for diabetes. Linkage mapping, positional cloning, and candidate gene studies have been most successful in the forms of diabetes with the simplest genetic models. Early studies characterizing diabetes resulting from mutations in *insulin* (*INS*) and *insulin receptor* (45) genes as well as the mitochondrial genome (46) provided important insights into glucose homeostasis, but it is the studies on MODY that provide the classic example of the successful application of genetics to diabetes (47, 48). Linkage mapping studies on MODY were quite successful, and within a few years, a combination of positional cloning and studies of positional candidate genes led to the identification of *glucokinase* (*GCK*) and *hepatocyte nuclear factors 4 α* and *1 α* (*HNF4A* and *TCF1*) as genes in which a single mutation could lead to the complex metabolic phenotype of diabetes (see ref. 49 for a recent review). *GCK* is the rate-limiting enzyme in glucose metabolism; *HNF4A* and *TCF1* are transcription factors expressed in a variety of tissues, including the liver and pancreas where they work in a transcription regulatory network to regulate the expression of genes involved in glucose transport and metabolism (49).


Once these genes had been implicated in MODY, a number of other transcription factors within the same regulatory network were also found to be MODY genes. As noted above, mutations in MODY genes, at the *INS* and *INS receptor* genes, or in the mitochondrial genome collectively account for only a small proportion of diabetes — about 1–5% (50). However, the monogenic forms of diabetes provide important insights into how we should be thinking about the genetic components of a phenotype as broad and metabolically complex as that of diabetes. The genes in which a single mutation is sufficient to generate this phenotype play an absolutely central role in glucose homeostasis (e.g., *INS*, the *INS receptor*, *GCK*) or are capable of affecting the regulation of many genes that act within this overall pathway (e.g., transcription factors). From these studies we learned that glucose homeostasis is a balance between insulin production, determined by β cell mass and/or function, and insulin action. Some of the genes that have been shown to affect these processes either in humans or experimental animals are illustrated in Figure 2.

The general observations on the genes implicated in monogenic forms of diabetes fit well within the emerging theories for how biological networks might be expected to perform and suggest that a systematic application of network theory to the metabolic and regulatory pathways underlying glucose homeostasis may provide a fruitful avenue for prioritizing genes for future studies. Recent research suggests that a scale-free topology is a nearly universal feature of networks, whether we are considering air traffic patterns,




review series


Normal glucose homeostasis




T1D



Early T2D



Late T2D



the Internet, or biological pathways in complex organisms (51–53). A network with scale-free topology is characterized by that there is a relatively small number of hubs that have substantially more connections than average, along with a much larger number of nodes that have a very limited number of other connections. Such networks can be very stable and robust but are most vulnerable at those hubs that have the most connections to other nodes. Using

Figure 2

Diabetes results from an imbalance between the insulin-producing capacity of the islet β cell and the requirement for insulin action in insulin target tissues such as liver, adipose tissue, and skeletal muscle. Some of the many genes that have been shown or could possibly contribute to the imbalance are illustrated.

network theory with even the information we already have about the pathways implicated in glucose homeostasis, we could predict that genes/proteins located at hubs that are the most highly interconnected are those most vulnerable to degrading the overall system. Thus, genetic variation at hub genes may be more likely to lead to detectable perturbations in glucose homeostasis. While we might use network theory to prioritize genes for study simply based on the relative connectedness of the genes at the hubs in the networks, it might also be useful to overlay such an analysis on existing information we have about potential genetic risk factors for diabetes via linkage mapping or linkage disequilibrium mapping studies. A similar strategy was recently applied in studies of Alzheimer disease, with promising results (54).

Genetic studies on T1D

Genetic linkage studies of T1D and T2D have been quite variable, spanning the spectrum of results generally observed for disorders with complex inheritance. T1D is unique among complex disorders in the magnitude of the familial risk attributable to a single locus, HLA. While *HLA* was originally implicated through association studies as a candidate gene (55), the magnitude of the evidence for linkage at HLA in T1D is larger than has been observed for a linkage in any other complex disorder, although some other autoimmune disorders also have strong evidence for linkage in the HLA region (56). Because of the major contribution of HLA to the familial risk of T1D, identification of the other genetic risk factors may be more akin to identifying modifier loci for monogenic disorders than identifying primary susceptibility loci for complex disorders. Indeed, the non-HLA genes that have been reproducibly characterized as T1D susceptibility loci have been identified largely through candidate gene studies.

Evidence for linkage at the non-HLA loci implicated in T1D has been uneven at best. For example, the very common class I alleles at *INS* variable number of tandem repeats (VNTR) are significantly overtransmitted from parents heterozygous for this allele to offspring affected with T1D (57). There was no evidence for linkage of the *INS* region to T1D in 100 affected sibling pair (ASP) families (58) and only modest evidence in more than 200 families (59). In a



large sample (767 families) including ASP families from both the US and the United Kingdom, there was significant evidence for linkage near *INS* (60). Similarly, initial evidence for linkage near *CTLA4*, another locus with support for affecting susceptibility to T1D through association studies, was detected in some individual samples, but little evidence for linkage in the region of *CTLA4* was found in larger, combined samples (60). Finally, *PTPN22*, a locus recently implicated as a candidate gene in T1D (61), rheumatoid arthritis (62), and systemic lupus erythematosus (63), shows little evidence for linkage to T1D even in relatively large samples (60).

Genetic studies on T2D

The success of linkage mapping for T2D has been similar to that observed for other complex disorders, which has been, regrettably, quite limited. More than 25 genome-wide screens have been conducted on samples from all over the world (for review, see ref. 44). Despite the number of studies, there are only a few regions with replicated evidence for linkage: 1q, 3q, 8p, 10q, 12q, and 20q. Even in these regions, however, evidence for linkage is far from universal (3–7 of the more than 25 studies show nominally significant evidence for linkage), peaks are broad, and it is unlikely that all studies with linkage signal in a given region reflect the contribution of the same susceptibility genes.

Factors contributing to the complexity of analysis

Why has linkage mapping been relatively unsuccessful in localizing susceptibility genes for T1D and T2D in even relatively large, combined data sets? The complexity of the underlying genetic model is clearly a contributing factor. We have almost certainly underestimated the number of different genetic risk factors for both disorders and overestimated the magnitude of effect that might be expected for any one of these loci, excepting, perhaps, HLA in T1D. It might be argued that the initial success with HLA in T1D, the first susceptibility gene successfully linked to a complex disorder, encouraged us to establish a series of unrealistic expectations for how genetic risk factors contribute to diabetes and other complex disorders. Among the complexities of the genetic models for complex disorders that are likely to contribute to the difficulties in linkage mapping are gene-gene and gene-environment interactions. Such interactions are difficult to accommodate in primary linkage mapping studies and yet are a requisite part of the definition of a complex trait. It is not clear whether these problems could be solved by increasing either the sample sizes for linkage studies or the number of phenotypes examined. In particular, the failure to adequately measure and account for nongenetic factors affecting risk of diabetes almost certainly has reduced our ability to successfully map genetic risk factors.

The diagnosis of diabetes has long been standardized and is both reliably and inexpensively achieved with a simple blood test. These factors contributed substantially to making diabetes the first complex disorder to be widely studied using genetic tools. But the diagnosis of diabetes is designed to focus on the clinical consequences of elevated blood glucose levels rather than the underlying genetic liability to this very complex metabolic disease. The simple dichotomous diagnosis masks a tremendous amount of clinical heterogeneity, and it is likely that the genetic heterogeneity of diabetes is at least as great as the clinical heterogeneity. Thus, efforts to specify more genetically homogeneous samples according to clinical characteristics might also be fruitful. For example, stratifying T1D families for linkage analyses according to antibody positiv-

ity, or patients with T2D by BMI, might lead to more consistent and reproducible results in linkage mapping studies. Additionally, analysis of quantitative traits that may be related to the primary dichotomous trait of T2D, such as insulin resistance, β cell mass and performance, BMI and other features of the metabolic syndrome, may lead to the identification of genes contributing to risk of T2D (64). Several such studies have been already been initiated (see ref. 65 for review), including a recent IRAS study of quantitative traits in African American and Hispanic families (66), and the results point to promising genomic regions, though no causative genes have yet been identified. In this regard, use of animal models could help in gene identification, as syntenic regions are being evaluated in congenic strains in order to narrow regions conveying genetic risk for T2D, as, for example, in obese mice (67). We must also recognize, however, that the quantitative phenotypes that we now know how to measure easily are not necessarily the phenotypes best able to characterize the genetic liability to T2D.

Emerging patterns and implications for study design

The patterns emerging from the linkage and association studies that have identified genetic risk factors for diabetes offer intriguing insights into the challenges we face in improving our study designs. Some of the factors are common but so low risk that they would be quite difficult to detect in linkage mapping studies. For example, the allele increasing risk of T2D at *PPARG* has a frequency of 0.85–0.95 in most of the world's populations (68) and is associated with very modest increase in risk. Similarly, the class I alleles (or polymorphisms in linkage disequilibrium with them) increasing risk for T1D at the *INS VNTR* are found at very high frequency in populations of European and Asian descent (0.70–0.85), but they increase risk only modestly (69). There are rarer amino acid polymorphisms that have been reliably associated with diabetes. For example, the allele increasing risk of T2D at the T504A polymorphism at *CAPN10* ranges in frequency from 0.04 to 0.16 (70), and the allele increasing risk of T1D at the R620W polymorphism at *PTPN22* ranges in frequency from 0.08 to 0.14 (69). But many of the polymorphisms associated with increased risk of diabetes identified to date are not amino acid polymorphisms. The variation at *CTLA4* implicated in T1D appears to affect splicing (71), while variation at the *INS VNTR* (69), at *CAPN10* (72), and at *HNF4A* (73, 74) (as discussed in more detail below) may affect gene expression. Linkage mapping, even with very large samples, will miss many of these risk factors. Similarly, genome-wide association mapping focused exclusively on common haplotypes will miss many of the rarer risk alleles. Strategies targeting known amino acid polymorphisms will miss rare, unknown susceptibility variants and may not detect the effects of the more common non-coding sequence polymorphisms either. Until it becomes clearer whether there will be a predominant frequency spectrum or polymorphism type in the genetic variation affecting susceptibility to diabetes (whether type 1 or 2), it seems prudent to adopt strategies that enable detection of susceptibility alleles with a wide range of frequencies and effects. Some known genes associated or linked with diabetes are listed in Table 1 (61, 70, 73, 74, 90–117).

Sample size for low-risk genes associations

Identification of susceptibility alleles for T1D, outside the HLA locus, and T2D, whether through positional cloning or in the context of studies on functional candidates, has been challenging. Initial positive results are usually only inconsistently replicated. For



review series

Table 1Some known genes associated or linked with diabetes by replication in at least 2 studies^A

Type	Gene	Gene name	Function	SNP or allele or locus or marker	Refs.
MODY 1	<i>HNF4A</i>	<i>Hepatocyte nuclear factor 4 α</i>	Transcription factor	Mutations in 13 families	90, 91
MODY 2	<i>GCK</i>	<i>Glucokinase</i>	Glucose metabolism	130 different mutations described	92, 93
MODY 3	<i>TCF1</i>	<i>Hepatocyte nuclear factor 1α</i>	Transcription factor	120 different mutations described in all racial ethnic backgrounds	93, 94
MODY 4	<i>IPF1</i>	<i>Insulin promoter factor 1</i>	Transcription factor	Rare mutations; 1 family described	95
MODY 5	<i>TCF2</i>	<i>Hepatocyte nuclear factor 1β</i>	Transcription factor	Rare mutations	96, 97
MODY 6	<i>NEUROD1</i>	<i>Neurogenic differentiation 1</i>	Transcription factor	Mutations described in 2 families with autosomal dominant form	98
T1D	<i>HLA</i>	<i>Human leukocyte antigen</i>	Immune system regulation	Variants in multiple genes	99, 100
T1D	<i>INS</i>	<i>Insulin</i>	Involved in numerous aspects of metabolism	VNTR	99, 101
T1D	<i>CTLA4</i>	<i>Cytotoxic T-lymphocyte-associated protein 4</i>	Immune system regulation	T17A	102, 103
T1D	<i>PTPN22</i>	<i>Protein tyrosine phosphate, non-receptor type 22</i>	Immune system regulation	SNP C1858T	61, 104
T2D	<i>ABCC8</i>	<i>ATP-binding cassette, subfamily C, sulfonylurea receptor</i>	Regulator of potassium channels and insulin release	SNPs in various exons	105, 106
T2D	<i>CAPN10</i>	<i>Calpain 10</i>	Protease	Various intronic SNP haplotypes	70, 107
T2D	<i>GCGR</i>	<i>Glucagon receptor</i>	Controls hepatic glucose production and insulin secretion	G40S	108, 109
T2D	<i>GCK</i>	<i>Glucokinase</i>	Glucose metabolism	Microsatellite in 3' end of gene	110, 111
T2D	<i>KCNJ11</i>	<i>Potassium inwardly-rectifying channel, subfamily J, member 11</i>	Regulation of insulin secretion	E23K	112, 113
T2D	<i>PPARG</i>	<i>Peroxisome proliferator-activated receptor γ</i>	Transcription factor	P12A	114, 115
T2D	<i>HNF4A</i>	<i>Hepatocyte nuclear factor 4 α</i>	Transcription factor	P2 promoter SNPs	73, 74
T2D	<i>SLC2A1</i>	<i>Glut 1</i>	Glucose transporter	XbaI(-) restriction site	116, 117

^Awith the exception of MODY 4 and MODY 6.

example, conflicting results of different studies on the Pro12Ala polymorphism in the *PPARG2* gene were resolved by analysis of large family and case control samples; and a meta-analysis of all published studies further demonstrated that this polymorphism does affect risk of T2D, but only to a small degree (68). Similarly the E23K polymorphism in the Kir6.2 subunit of the ATP-regulated potassium channel has been shown by meta-analysis to contribute a small but significant risk to the disease in the populations studied (75, 76). Except for HLA in T1D, the susceptibility alleles for T1D and T2D quite modestly affect risk of disease, which mandates the study of large sample sizes. This argues for large collaborative studies, wherein sample sizes will be on the order of thousands and replication will be conducted during the primary investigation rather than through the time-consuming process of publication of multiple individual studies.

Investigating potential regulatory regions of candidate genes through haplotype-tagged SNPs

While every nonsynonymous coding single nucleotide polymorphism (SNP) in candidate genes should be tested for possible contribution to disease susceptibility, 2 recent studies highlight the importance of conducting association studies with markers in potential regulatory regions. Earlier studies with SNPs in or near the coding region of *HNF4A*, a gene previously shown to be mutated in rare cases of MODY (77), had yielded no association with T2D (78). More recently, it was discovered that a second promoter exists 40 kb upstream of the gene (79, 80) and that SNPs in the region of this second promoter and in other parts of the

noncoding sequence of *HNF4A* were associated with T2D in Ashkenazi Jews (74) and in a sample in Finland (73). Results of follow-up studies in other populations may provide some confirmation of the association between T2D and noncoding SNPs at *HNF4A* and its regulatory regions (81), but we should not be surprised if some studies in even large replication samples fail to observe associations and should be equally prepared for the possibility that not all studies will identify the very same polymorphisms as showing association. The nature of regulatory variation virtually insures that effects attributable to one polymorphism might be attenuated by effects of a second polymorphism – thus, the cumulative effects of regulatory variants may be poorly predicted by the marginal effects measured for any individual variant.

DNA diagnostics and pharmacogenetics in clinical trials

The use of genomic tools provided by the Human Genome Project offers the opportunity to identify individuals at risk, classify subtypes of the disease, choose therapy based on more accurate diagnosis (82), more precisely delineate the environmental factors that contribute to the onset and progression of the disease and its complications, and monitor responses to therapy (83, 84). Recently, genetic information was applied to clinical diabetes management in a randomized crossover trial of gliclazide, an agent affecting insulin secretion, and metformin, an agent that enhances insulin action. Compared with patients with typical T2D, patients with diabetes caused by a particular MODY mutation in *TCF1* (85) had a 4- to 5-fold greater response to gliclazide than to metformin. Another example was the recent finding of heterozygous mutations



in the ATP-sensitive K⁺ channel subunit of the *Kir6.2* gene in 7 of 11 patients with neonatal diabetes (86). This gene plays a critical role in glucose-stimulated insulin secretion. Remarkably, several patients who previously required insulin injections were taken off insulin and treated with oral medication, which again illustrates the efficacy of pharmacogenetics for treatment of some diabetics.

A large number of clinical trials for both T1D and T2D are currently being conducted. The Type 1 Diabetes Genetics Consortium (T1DGC; <http://www.t1dgc.org>) will organize international efforts to identify genes that determine an individual's risk of T1D through the identification of 2,500 new families with 2 or more affected siblings. To explore approaches to treatment of T2D in youth, the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth; <http://www.TODAYstudy.org>) study will enroll 750 children and teenagers that have recently been diagnosed with T2D. Participants will be assigned to groups for treatment aimed at weight reduction and increasing physical activity. The Look AHEAD (Action for Health in Diabetes) trial is a multicenter, randomized clinical trial that will examine the consequences of a lifestyle intervention designed to achieve and maintain weight loss over the long term through decreased caloric intake and increased exercise in 5,000 obese patients with T2D. The National Heart, Lung, and Blood Institute-led Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is designed to test the effects of glycemia and blood pressure control on major CVD events and the use of fibrate treatment to increase HDL cholesterol and lower triglycerides (<http://www.accordtrial.org/public/index.cfm>). The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial (<http://www.bari2d.org>) addresses questions about therapy in adults with T2D and stable CAD who might be candidates for revascularization. These studies represent ideal opportunities to incorporate DNA diagnostic testing and assessment of variable responses to therapeutic interventions.

Large prospective cohort study for the effects of genes and environment on diabetes

While case-control studies have much to offer for the assessment of the interactions between genes and environmental factors, Francis Collins noted that clinically diagnosed cases may represent only the more severely affected individuals with the disease and highlighted the difficulties of selecting an unbiased control group (87). To more accurately quantify genetic contribution and population-wide risk, he proposed prospective, population-based cohort studies (88). In a

case-control study, there would be no samples available from cases prior to the onset of disease to search for predictive markers. A prospective study of 200,000 people would likely yield more than 5,000 cases of diabetes, based on current prevalence, in addition to numerous other features of the metabolic syndrome such as obesity, hyperinsulinism, dyslipidemia, hypertension, and CVD. This population, if also studied with high-throughput, low-cost genotyping, could represent a major resource for physician-scientists to accelerate the incorporation of genetics into clinical medicine.

Unanswered questions and future opportunities

Many of the questions raised here cannot yet be answered. Will genome-wide association studies work in a way that genome-wide linkage mapping studies did not? Will the identification of more homogeneous subsets of patients be the key to making any real headway in either association or linkage mapping studies? Are non-genetic risk factors largely uniform, or are they perhaps as variable as genetic risk factors? Will we really get improvement in understanding with a "better" version of more of the same, or do we need to move to something qualitatively different? Genomic technology is advancing rapidly, and larger, higher-powered studies will soon be possible — these studies should allow us to address these questions. The challenge now is for clinical scientists to provide well-characterized populations with carefully recorded phenotypic and environmental data. This challenge will extend to the acquisition of new organizational skills to collate these data from many centers and provide integration with the large volume of genetic data soon to be generated (89). The opportunities are great for future diabetes genetic epidemiology research to provide clinically useful information, the most vital goal of the Human Genome Project.

Acknowledgments

The authors wish to acknowledge NIH grants DK049583 ("Metabolic Basis of NIDDM: A Sib Pair Analysis") and DK58026 ("International Type 2 Linkage Consortium"); and Ping An, Richard Bergman, Ernesto Bernal-Mizrachi, Rudy Leibel, and Mike Province for helpful discussions and suggestions regarding the manuscript. Corentin Cras-Meneure helped with illustrations as well as discussions.

Address correspondence to: M. Alan Permutt, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8127, St. Louis, Missouri 63110-1010, USA. Phone: (314) 362-8680; Fax: (314) 747-2692; E-mail: apermutt@im.wustl.edu.

- Porte, D., Sherwin, R.S., and Baron, A. 2003. *Ellenberg & Rifkin's diabetes mellitus*. McGraw-Hill. New York, New York, USA. 1047 pp.
- Zimmet, P., Shaw, J., and Alberti, K.G. 2003. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. *Diabet. Med.* **20**:693-702.
- Misra, A., and Vikram, N.K. 2004. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. *Nutrition*. **20**:482-491.
- Meigs, J.B., et al. 2003. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. *Diabetes*. **52**:2160-2167.
- Hirsch, I.B. 2004. Blood glucose monitoring technology: translating data into practice. *Endocr. Pract.* **10**:67-76.
- WHO. Diabetes program. <http://www.who.int/diabetes/en/>.
- Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W., and Williamson, D.F. 2003. Lifetime risk for diabetes mellitus in the United States. *JAMA*. **290**:1884-1890.
- Centers for Disease Control and Prevention. 2005. Diabetes maps. Maps — diabetes and gestational diabetes trends among adults in the United States, behavioral risk factor surveillance system: 1990, 1995 and 2001. <http://www.cdc.gov/diabetes/statistics/maps/index.htm>.
- Centers for Disease Control and Prevention. 2005. Overweight and obesity: obesity trends: U.S. obesity trends 1985-2003. <http://www.cdc.gov/nccd-dnpa/obesity/trend/maps/index.htm>.
- Alberti, G., et al. 2004. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. *Diabetes Care*. **27**:1798-1811.
- Centers for Disease Control and Prevention. 2005. National diabetes fact sheet: national estimates on diabetes. <http://www.cdc.gov/diabetes/pubs/estimates.htm#prev>.
- Engelgau, M.M., et al. 2004. The evolving diabetes burden in the United States. *Ann. Intern. Med.* **140**:945-950.
- The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* **329**:977-986.
- Stamler, J., Vaccaro, O., Neaton, J.D., and Wentworth, D. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*. **16**:434-444.
- Kitagawa, T., Owada, M., Urakami, T., and Yamauchi, K. 1998. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. *Clin. Pediatr. (Phila.)* **37**:111-115.
- Bhargava, S.K., et al. 2004. Relation of serial chang-



review series

- es in childhood body-mass index to impaired glucose tolerance in young adulthood. *N. Engl. J. Med.* **350**:865–875.
17. Hogan, P., Dall, T., and Nikolov, P. 2003. Economic costs of diabetes in the US in 2002. *Diabetes Care.* **26**:917–932.
 18. Morala, A.A., Omar, M.A., and Pirie, F.J. 2003. Diabetes in Africa. Epidemiology of type 1 and type 2 diabetes in Africa. *J. Cardiovasc. Risk.* **10**:77–83.
 19. Rotimi, C.N., et al. 2001. In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study. *Ann. Epidemiol.* **11**:51–58.
 20. Zimmet, P.Z. 1999. Diabetes epidemiology as a tool to trigger diabetes research and care. *Diabetologia.* **42**:499–518.
 21. Hu, F.B., et al. 2001. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N. Engl. J. Med.* **345**:790–797.
 22. Speakman, J.R. 2004. Obesity: the integrated roles of environment and genetics [review]. *J. Nutr.* **134**(8 Suppl.):2090S–2105S.
 23. Dalton, M., et al. 2003. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. *J. Intern. Med.* **254**:555–563.
 24. Neel, J.V. 1999. The “thrifty genotype” in 1998 [review]. *Nutr. Rev.* **57**:S2–S9.
 25. Hales, C.N., et al. 1991. Fetal and infant growth and impaired glucose tolerance at age 64. *BMJ.* **303**:1019–1022.
 26. Hales, C.N., and Barker, D.J. 2001. The thrifty phenotype hypothesis. *Br. Med. Bull.* **60**:5–20.
 27. NIH, Office of Extramural Research. 2003. The fetal basis of adult disease: role of the environment [program announcement PAR-03-121]. <http://grants2.nih.gov/grants/guide/pa-files/PAR-03-121.html>.
 28. Burcelin, R., Crivelli, V., Dacosta, A., Roy-Tirelli, A., and Thorens, B. 2002. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. *Am. J. Physiol. Endocrinol. Metab.* **282**:E834–E842.
 29. Ozcan, U., et al. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science.* **306**:457–461.
 30. Randle, P.J., Garland, P.B., Hales, C.N., and Newsholme, E.A. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *Lancet.* **1**:785–789.
 31. Rothman, D.L., Shulman, R.G., and Shulman, G.I. 1992. ³¹P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. *J. Clin. Invest.* **89**:1069–1075.
 32. Shulman, G.I. 2004. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. *Physiology (Bethesda).* **19**:183–190.
 33. Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., and Shulman, G.I. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N. Engl. J. Med.* **350**:664–671.
 34. Matthews, D.R. 1999. The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study. *Diabetes Obes. Metab.* **1**(Suppl. 2):S7–S13.
 35. Redondo, M.J., Fain, P.R., and Eisenbarth, G.S. 2001. Genetics of type 1A diabetes. *Recent Prog. Horm. Res.* **56**:69–89.
 36. Beck-Nielsen, H., Vaag, A., Poulsen, P., and Gaster, M. 2003. Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects – experiences from relatives and twin studies. *Best Pract. Res. Clin. Endocrinol. Metab.* **17**:445–467.
 37. Florez, J.C., Hirschhorn, J., and Altshuler, D. 2003. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. *Annu. Rev. Genomics Hum. Genet.* **4**:257–291.
 38. Poulsen, P., Kyvik, K.O., Vaag, A., and Beck-Nielsen, H. 1999. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin study. *Diabetologia.* **42**:139–145.
 39. Mills, G.W., et al. 2004. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. *Diabetologia.* **47**:732–738.
 40. Hanson, R.L., et al. 2001. Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians. *Diabetes Metab. Res. Rev.* **17**:296–303.
 41. Austin, M.A., et al. 2004. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese Americans. *Diabetes.* **53**:1166–1169.
 42. Henkin, L., et al. 2003. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. *Ann. Epidemiol.* **13**:211–217.
 43. Perusse, L., et al. 2000. Familial aggregation of amount and distribution of subcutaneous fat and their responses to exercise training in the HERITAGE family study. *Obes. Res.* **8**:140–150.
 44. McCarthy, M.I. 2003. Growing evidence for diabetes susceptibility genes from genome scan data. *Curr. Diab. Rep.* **3**:159–167.
 45. Musso, C., et al. 2004. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. *Medicine (Baltimore).* **83**:209–222.
 46. Maassen, J.A., et al. 2004. Mitochondrial diabetes: molecular mechanisms and clinical presentation. *Diabetes.* **53**(Suppl. 1):S103–S109.
 47. Permutt, M.A., and Hattersley, A.T. 2000. Searching for type 2 diabetes genes in the post-genome era. *Trends Endocrinol. Metab.* **11**:383–393.
 48. Shih, D.Q., and Stoffel, M. 2002. Molecular etiologies of MODY and other early-onset forms of diabetes. *Curr. Diab. Rep.* **2**:125–134.
 49. Fajans, S.S., Bell, G.I., and Polonsky, K.S. 2001. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N. Engl. J. Med.* **345**:971–980.
 50. Ledermann, H.M. 1995. Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? [letter.] *Diabetologia.* **38**:1482.
 51. Jeong, H., Tombor, B., Albert, R., Oltvai, Z.N., and Barabasi, A.L. 2000. The large-scale organization of metabolic networks. *Nature.* **407**:651–654.
 52. Barabasi, A.L., and Oltvai, Z.N. 2004. Network biology: understanding the cell's functional organization. *Nat. Rev. Genet.* **5**:101–113.
 53. Almaas, E., Kovacs, B., Vicsek, T., Oltvai, Z.N., and Barabasi, A.L. 2004. Global organization of metabolic fluxes in the bacterium *Escherichia coli*. *Nature.* **427**:839–843.
 54. Krauthammer, M., Kaufmann, C.A., Gilliam, T.C., and Rzhetsky, A. 2004. Molecular triangulation: bridging linkage and molecular-network information for identifying candidate genes in Alzheimer's disease. *Proc. Natl. Acad. Sci. U. S. A.* **101**:15148–15153.
 55. Cudworth, A.G., and Woodrow, J.C. 1975. Evidence for HL-A-linked genes in “juvenile” diabetes mellitus. *Br. Med. J.* **3**:133–135.
 56. John, S., et al. 2004. Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. *Am. J. Hum. Genet.* **75**:54–64.
 57. Spielman, R.S., McGinnis, R.E., and Ewens, W.J. 1993. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am. J. Hum. Genet.* **52**:506–516.
 58. Cox, N.J., and Spielman, R.S. 1989. The insulin gene and susceptibility to IDDM. *Genet. Epidemiol.* **6**:65–69.
 59. Concannon, P., et al. 1998. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. *Nat. Genet.* **19**:292–296.
 60. Cox, N.J., et al. 2001. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. *Am. J. Hum. Genet.* **69**:820–830.
 61. Bottini, N., et al. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. *Nat. Genet.* **36**:337–338.
 62. Begovich, A.B., et al. 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am. J. Hum. Genet.* **75**:330–337.
 63. Kyogoku, C., et al. 2004. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. *Am. J. Hum. Genet.* **75**:504–507.
 64. Watanabe, R.M., et al. 1999. Genome wide linkage analysis of type 2 diabetes-related quantitative traits in the FUSION study. *Diabetes Abstract Book.* **48**(Suppl. 1):A46.
 65. Hanson, R.L., and Knowler, W.C. 2003. Quantitative trait linkage studies of diabetes-related traits. *Curr. Diab. Rep.* **3**:176–183.
 66. Rich, S.S., et al. 2004. Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. *Diabetes.* **53**:1866–1875.
 67. Valdar, W.S., Flint, J., and Mott, R. 2003. QTL fine-mapping with recombinant-inbred heterogeneous stocks and in vitro heterogeneous stocks. *Mamm. Genome.* **14**:830–838.
 68. Altshuler, D., et al. 2000. The common PPARγ prol12ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat. Genet.* **26**:76–80.
 69. Barratt, B.J., et al. 2004. Remapping the insulin gene/IDDM2 locus in type 1 diabetes. *Diabetes.* **53**:1884–1889.
 70. Weedon, M.N., et al. 2003. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. *Am. J. Hum. Genet.* **73**:1208–1212.
 71. Ueda, H., et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature.* **423**:506–511.
 72. Horikawa, Y., et al. 2000. Genetic variation in the calpain 10 gene (CAPN10) is associated with type 2 diabetes mellitus [erratum 2000, **26**:502]. *Nat. Genet.* **26**:163–175.
 73. Silander, K., et al. 2004. Genetic variation near the hepatocyte nuclear factor-4α gene predicts susceptibility to type 2 diabetes. *Diabetes.* **53**:1141–1149.
 74. Love-Gregory, L.D., et al. 2004. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4α gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an Ashkenazi Jewish population. *Diabetes.* **53**:1134–1140.
 75. Love-Gregory, L., et al. 2003. E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARγ Pro12Ala variant. *Diabetologia.* **46**:136–137.
 76. Gloyn, A.L., et al. 2003. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. *Diabetes.* **52**:568–572.
 77. Lausen, J., et al. 2000. Naturally occurring mutations in the human HNF4α gene impair the func-



- tion of the transcription factor to a varying degree. *Nucleic Acids Res.* **28**:430–437.
78. Ghosh, S., et al. 1999. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. *Proc. Natl. Acad. Sci. U. S. A.* **96**:2198–2203.
 79. Thomas, H., et al. 2001. A distant upstream promoter of the HNF-4 α gene connects the transcription factors involved in maturity-onset diabetes of the young. *Hum. Mol. Genet.* **10**:2089–2097.
 80. Hansen, S.K., et al. 2002. Genetic evidence that HNF-1 α -dependent transcriptional control of HNF-4 α is essential for human pancreatic β cell function. *J. Clin. Invest.* **110**:827–833. doi:10.1172/JCI200215085.
 81. Weedon, M.N., et al. 2004. Common variants of the hepatocyte nuclear factor-4 P2 promoter are associated with type 2 diabetes in the U.K. population. *Diabetes*. **53**:3002–3006.
 82. Shepherd, M., and Hattersley, A.T. 2004. 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. *Clin. Med.* **4**:144–147.
 83. Bentley, D.R. 2004. Genomes for medicine. *Nature*. **429**:440–445.
 84. Bell, J. 2004. Predicting disease using genomics. *Nature*. **429**:453–456.
 85. Pearson, E.R., et al. 2003. Genetic cause of hyperglycaemia and response to treatment in diabetes. *Lancet*. **362**:1275–1281.
 86. Sagen, J.V., et al. 2004. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. *Diabetes*. **53**:2713–2718.
 87. Collins, F.S. 2004. The case for a US prospective cohort study of genes and environment. *Nature*. **429**:475–477.
 88. Whelton, P.K., and Gordis, L. 2000. Epidemiology of clinical medicine. *Epidemiol. Rev.* **22**:140–144.
 89. Altshuler, J.S., and Altshuler, D. 2004. Organizational challenges in clinical genomic research. *Nature*. **429**:478–481.
 90. Yamagata, K., et al. 1996. Mutations in the hepatocyte nuclear factor-4 α gene in maturity-onset diabetes of the young (MODY1). *Nature*. **384**:458–460.
 91. Lindner, T., et al. 1997. Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4 α /MODY1 gene. *J. Clin. Invest.* **100**:1400–1405.
 92. Gidh-Jain, M., et al. 1993. Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. *Proc. Natl. Acad. Sci. U. S. A.* **90**:1932–1936.
 93. Barrio, R., et al. 2002. Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. *J. Clin. Endocr. Metab.* **87**:2532–2539.
 94. Yamagata, K., et al. 1996. Mutations in the hepatocyte nuclear factor-1 α gene in maturity-onset diabetes of the young (MODY3). *Nature*. **384**:455–457.
 95. Stoffers, D.A., Ferrer, J., Clarke, W.L., and Habener, J.F. 1997. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1 [letter]. *Nat. Genet.* **17**:138–141.
 96. Lindner, T.H., et al. 1999. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1-beta. *Hum. Mol. Genet.* **8**:2001–2008.
 97. Horikawa, Y., et al. 1997. Mutation in hepatocyte nuclear factor-1-beta gene (TCF2) associated with MODY [letter]. *Nat. Genet.* **17**:384–385.
 98. Malecki, M.T., et al. 1999. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. *Nat. Genet.* **23**:323–328.
 99. Davies, J.L., et al. 1994. A genome-wide search for human type 1 diabetes susceptibility genes. *Nature*. **371**:130–136.
 100. Hashimoto, L., et al. 1994. Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. *Nature*. **371**:161–164.
 101. Mein, C.A., et al. 1998. A search for type 1 diabetes susceptibility genes in families from the United Kingdom. *Nat. Genet.* **19**:297–300.
 102. Donner, H., et al. 1997. CTLA4 Alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. *J. Clin. Endocrinol. Metab.* **82**:143–146.
 103. Marron, M.P., et al. 1997. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. *Hum. Mol. Genet.* **6**:1275–1282.
 104. Smyth, D., et al. 2004. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. *Diabetes*. **53**:3020–3023.
 105. Inoue, H., et al. 1996. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. *Diabetes*. **45**:825–831.
 106. Hani, E.H., et al. 1997. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. *Diabetes*. **46**:688–694.
 107. del Bosque-Plata, L., et al. 2004. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. *Mol. Genet. Metab.* **81**:122–126.
 108. Hager, J., et al. 1995. A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. *Nat. Genet.* **9**:299–304.
 109. Gough, S.C., et al. 1995. Mutation of the glucagon receptor gene and diabetes mellitus in the UK: association or founder effect? *Hum. Mol. Genet.* **4**:1609–1612.
 110. Chiu, K.C., et al. 1992. A genetic marker at the glucokinase gene locus for type 2 (non-insulin-dependent) diabetes mellitus in Mauritian Creoles. *Diabetologia*. **35**:632–638.
 111. McCarthy, M.I., et al. 1994. Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in a cohort of elderly Finnish men. *Diabetes Med.* **11**:198–204.
 112. Hani, E.H., et al. 1998. Missense mutations in the pancreatic islet beta cell inwardly rectifying K⁺ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. *Diabetologia*. **41**:1511–1515.
 113. Gloyn, A.L., et al. 2001. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). *Diabetes Med.* **18**:206–212.
 114. Deeb, S.S., et al. 1998. A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat. Genet.* **20**:284–287.
 115. Hara, K., et al. 2000. The Pro12Ala polymorphism in PPAR γ 2 may confer resistance to type 2 diabetes. *Biochem. Biophys. Res. Commun.* **271**:212–216.
 116. Li, S.R., Baroni, M.G., Oelbaum, R.S., Stock, J., and Galton, D.J. 1988. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. *Lancet*. **2**:368–370.
 117. Tao, T., et al. 1995. HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. *Diabetologia*. **38**:942–947.